SION logo

SION Sionna Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$2.97
-0.10 (-3.10%)

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, …

Market Cap: $134.35Mwww.sionnatx.com

Price

$5.10-87.39%
$4.50$20.01$35.53$51.04
May 4Aug 11

Social Signal Score

31
5d
—
30d
30
1 mentions
+0.0%
60d
40
2 mentions
+0.0%
90d
23
6 mentions
+0.0%
news: 6

Analyst Ratings

8 analysts
Holdconsensus
Strong Buy 0Buy 3Hold 4Sell 1Strong Sell 0
Avg price target$27.4+822.6%
Low $5Median $7High $60
Current Consensus

Revenue

$0.00
$0.00
Dec 2023Sep 2026

Analyst Estimates

FY2025
$-2.00
$-2.10–$-1.84
5 analysts
FY2026
$-2.57
$-2.74–$-2.44
7 analysts
FY2027
$-2.17
$-2.97–$-1.77
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Michael Cloonan
Sector
Healthcare
Industry
Biotechnology
Employees
59
Beta
1.22
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
1.41
www.sionnatx.com